Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded

MYRIAD GENETICS INC

Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.
Interest rate of one-month SOFR + 6.50%, with a 2.50% SOFR floor; matures July 31, 2030.
Proceeds for working capital, general corporate purposes, and refinancing existing ABL facility.
Credit facility is secured by substantially all assets of Myriad and its subsidiaries.
Company now has access to over $200M in capital (including cash) to support growth strategy.

item 1.01item 2.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.